the first , is the likelihood that in the therapeutic use of l-dopa in states of chronic dopaminergic nerve degeneration ( e.g . parkinson 's disease ) , the synthesis and metabolism of dopamine probably occurs throughout the entire central nervous system .
C0023570
l-dopa
C0030567
parkinson 's disease